Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis ; volume:25 ; number:1 ; day:17 ; month:7 ; year:2021 ; pages:1-9 ; date:12.2021
Critical care ; 25, Heft 1 (17.7.2021), 1-9, 12.2021
- Creator
-
Pařízková, Renata Černá
Martínková, Jiřina
Havel, Eduard
Šafránek, Petr
Kaška, Milan
Astapenko, David
Bezouška, Jan
Chládek, Jaroslav
Černý, Vladimír
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13054-021-03680-9
- URN
-
urn:nbn:de:101:1-2021102100022625643505
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pařízková, Renata Černá
- Martínková, Jiřina
- Havel, Eduard
- Šafránek, Petr
- Kaška, Milan
- Astapenko, David
- Bezouška, Jan
- Chládek, Jaroslav
- Černý, Vladimír
- SpringerLink (Online service)
Other Objects (12)
Population pharmacokinetics of meropenem in critically ill patients
Meropenem: continuous or extended infusion?
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
Comparative plasma and interstitial tissue fluid pharmacokinetics of meropenem demonstrate the need for increasing dose and infusion duration in obese and non-obese patients
Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors
Population pharmacokinetics of meropenem in critically ill patients
Meropenem: continuous or extended infusion?
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
Comparative plasma and interstitial tissue fluid pharmacokinetics of meropenem demonstrate the need for increasing dose and infusion duration in obese and non-obese patients
Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors
Population pharmacokinetics of meropenem in critically ill patients
Meropenem: continuous or extended infusion?
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients
Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
Comparative plasma and interstitial tissue fluid pharmacokinetics of meropenem demonstrate the need for increasing dose and infusion duration in obese and non-obese patients
Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients